Feel Free To Contact Us at
Subscribe to our Newsletter and get the latest updates in the field of Holistic Medicine
Testosterone replacement therapy (TRT) can benefit men with clinically confirmed testosterone deficiency. Depending on the individual, treatment may improve sexual desire, certain aspects of sexual function, lean body mass, bone mineral density, and some cases of unexplained anemia.
However, TRT is not a universal solution for fatigue, weight gain, reduced motivation, or the effects of aging. It can also suppress sperm production, increase red blood cell concentration, affect blood pressure, and require ongoing monitoring
Four important research studies offer insights into treatment goals, testosterone levels in healthier men, symptom assessment, and cardiovascular safety. Together, they highlight why treatment decisions should consider more than a single blood test.
TRT may be appropriate when a man has compatible symptoms and consistently low testosterone levels. Before starting, he should understand the potential benefits, risks, fertility implications, and monitoring requirements with a qualified healthcare professional.
Testosterone is an important hormone involved in several aspects of male health. It supports sexual development, libido, sperm production, muscle and bone health, and red blood cell production. It also contributes to aspects of mood and overall physical function.
Testosterone levels can change with age, but aging is not the only factor involved. Obesity, chronic illness, poor sleep, certain medications, and conditions affecting the testes or pituitary gland can also influence hormone production.
When testosterone levels are consistently low and a man experiences related symptoms, clinicians may investigate a condition called male hypogonadism.
Some symptoms associated with testosterone deficiency include:
The four research papers provide different perspectives on testosterone replacement therapy. Some examine treatment goals and symptom assessment, while others explore testosterone concentrations and cardiovascular outcomes.
Understanding what each study can—and cannot—establish is important when evaluating whether TRT may be appropriate.
One important question in testosterone treatment is whether the main objective should be restoring testosterone concentrations to an appropriate range or improving the symptoms associated with deficiency.
Research examining this question highlights the importance of setting clear treatment goals and evaluating both hormone levels and clinical outcomes.
Restoring testosterone concentrations to an appropriate range is an important treatment objective. However, a laboratory result alone cannot establish whether a patient is experiencing meaningful improvement.
For example, a man may achieve testosterone levels within the intended treatment range but continue experiencing fatigue, reduced motivation, or sexual difficulties. These symptoms may have other contributing causes and may require separate evaluation.
Treatment responses also differ depending on the outcome being assessed. Changes in sexual desire, muscle mass, body composition, and bone mineral density do not necessarily occur at the same rate or to the same degree.
Before treatment begins, patients and clinicians should identify the symptoms that matter most and establish realistic goals.
The research discussing treatment goals is a review, not a large randomized trial proving that one particular treatment target produces superior long-term outcomes. Its value lies in explaining why laboratory measurements and patient-reported symptoms need to be interpreted together.
02
Research examining testosterone concentrations in lean, never-smoking men without selected age-associated medical conditions provides useful insight into how hormone levels vary across different age groups.
The analysis used data from two National Health and Nutrition Examination Survey periods. It found that testosterone concentrations differed with age even among men selected for relatively good health.
| Age group | First survey period | Second survey period |
|---|---|---|
| 20–39 years | 624 ng/dL | 626 ng/dL |
| 40–59 years | 537 ng/dL | 586 ng/dL |
| 60 years and older | 461 ng/dL | 422 ng/dL |
Testosterone levels are influenced by several factors, including age, body composition, metabolic health, sleep, medications, and underlying medical conditions.
A result that appears low should therefore be interpreted in the context of the patient’s symptoms, health history, laboratory method, and appropriate reference range.
The research was observational and cross-sectional. It cannot establish that maintaining testosterone at the levels observed in these healthier men prevents disease, improves longevity, or guarantees better health outcomes.
It also does not prove that testosterone naturally declines at the same rate in every man.
03
Symptoms play an important role in evaluating possible testosterone deficiency. However, concerns such as fatigue, reduced strength, low mood, and decreased sexual desire can have several possible causes.
A quantitative version of the Androgen Deficiency in the Aging Male questionnaire, known as qADAM, was developed to help assess the severity of symptoms.
In the research, 57 men scheduled for radical prostatectomy completed the questionnaire. Only 34 had testosterone measurements available for comparison. The questionnaire scores showed statistically significant correlations with testosterone measurements and other measures of sexual and hormonal health.
A structured questionnaire may help patients describe symptoms that are otherwise difficult to communicate during an appointment. It can also provide a baseline for tracking changes after treatment begins.
For example, a patient may document changes in sexual desire, energy, or erectile function and discuss them with the prescribing clinician during follow-up.
The study involved a small and specific group of men preparing for prostate cancer surgery. Testosterone measurements were also collected at different times of the day rather than under a standardized morning testing protocol.
These limitations matter when interpreting how well the questionnaire can identify testosterone deficiency in the general population.
A qADAM or ADAM score cannot independently confirm hypogonadism. It should not replace blood testing, medical history, physical examination, or clinical evaluation.
04
One of the most important concerns surrounding testosterone replacement therapy has been its potential effect on cardiovascular health.
A large randomized, double-blind, placebo-controlled clinical trial investigated this question in more than 5,200 men between 45 and 80 years of age.
Participants had symptoms consistent with testosterone deficiency, two fasting testosterone measurements below 300 ng/dL, and either existing cardiovascular disease or an increased risk of cardiovascular disease.
They received either daily 1.62% testosterone gel or a placebo gel. The average treatment duration was approximately 22 months, while the average follow-up period was approximately 33 months.
The primary outcome was a combination of cardiovascular death, nonfatal heart attack, and nonfatal stroke.
| Outcome | Testosterone group | Placebo group |
|---|---|---|
| Major adverse cardiovascular events | 7.0% | 7.3% |
The primary cardiovascular outcome occurred at similar rates in both groups. The trial demonstrated that testosterone treatment was noninferior to placebo for this specific cardiovascular outcome in the population studied.
The trial provides reassurance that, under the conditions studied, testosterone gel did not produce a higher rate of the primary cardiovascular outcome compared with placebo.
However, it does not mean TRT is risk-free.
The findings cannot automatically be applied to every man, every testosterone formulation, every dose, or decades of continuous treatment. The trial also does not settle every question about long-term cardiovascular and other health outcomes.
When a man has clinically confirmed testosterone deficiency, TRT may provide meaningful benefits. The degree of improvement depends on the underlying cause, the symptoms being treated, and the individual’s response.
The benefits should also be understood in context: evidence of improvement in a particular outcome does not mean every patient will experience that improvement.
Testosterone plays an important role in male sexual health. In men with confirmed deficiency, treatment may improve sexual desire and certain aspects of sexual function. However, erectile dysfunction can also result from vascular disease, diabetes, psychological factors, medication effects, and other health conditions.
Testosterone contributes to the maintenance of muscle mass. TRT may increase lean body mass in men with testosterone deficiency. However, an increase in lean mass does not necessarily mean a substantial improvement in strength, endurance, or everyday physical function.
Testosterone supports bone formation and maintenance. In men with low testosterone, treatment may improve bone mineral density.
Testosterone influences red blood cell production. In some men with testosterone deficiency, treatment may improve unexplained anemia.
Some men with testosterone deficiency report low mood, reduced motivation, or difficulty concentrating.Treatment may improve certain symptoms in appropriately diagnosed patients. However, depression, anxiety, chronic stress, and sleep problems can have multiple causes and may require separate evaluation.
The possible benefits of testosterone therapy need to be considered alongside its risks. Some effects are related to testosterone’s influence on reproductive hormones and blood production, while others require ongoing monitoring.
One of the most important risks is the suppression of the body’s natural reproductive hormone signaling.
When testosterone is supplied externally, the brain may reduce its release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This can reduce testosterone production inside the testes and interfere with sperm production.
As a result, TRT can significantly reduce sperm counts and may cause infertility during treatment.
Testosterone can stimulate red blood cell production. In some patients, this may cause erythrocytosis, an increase in red blood cell concentration.
An elevated hematocrit can increase blood viscosity and may require dose adjustment, temporary treatment interruption, or further medical evaluation.
Testosterone treatment may increase blood pressure.
Following blood pressure monitoring studies, the FDA required testosterone product labeling changes to communicate this risk. Men with hypertension or cardiovascular risk factors should discuss blood pressure monitoring before and during treatment.
The major cardiovascular safety trial did not find an increased rate of its primary cardiovascular outcome. However, higher incidences of atrial fibrillation and pulmonary embolism were observed in the testosterone group.
Testosterone can increase sebaceous gland activity, potentially contributing to acne or oily skin.
Some men may also experience fluid retention or swelling. These effects can vary depending on the formulation, dose, and individual response.
Testosterone treatment can affect prostate-related measurements, including prostate-specific antigen (PSA).
Prostate health should be assessed according to the patient’s age, symptoms, family history, and individual risk factors.
Men with a history of prostate disease, concerning urinary symptoms, or abnormal prostate findings should discuss appropriate evaluation with their clinician before starting TRT.
Not every man with a low testosterone result is an appropriate candidate for treatment.
Clinical guidelines identify several situations in which TRT should not be started without further assessment or specialist involvement.
These include:
External testosterone can suppress sperm production and interfere with fertility.
Further specialist assessment is necessary before considering treatment.
An already high red blood cell concentration can increase concerns about further elevation during treatment.
This condition should be assessed and appropriately managed.
Their cardiovascular condition requires evaluation and stabilization.
Clinical guidance advises against initiating TRT within six months of these events.
Conditions that increase the tendency to develop blood clots require careful specialist assessment.
Significant urinary symptoms should be evaluated before treatment.
This list is not a substitute for a medical assessment. Some situations are contraindications under specific clinical guidelines, while others require individualized risk assessment.
A diagnosis should not be based on symptoms alone or on one low laboratory result.
Clinical guidelines recommend diagnosing hypogonadism in men who have compatible symptoms and signs alongside consistently low testosterone concentrations.
A responsible evaluation generally includes:
The clinician should discuss sexual health, energy, mood, sleep, medications, medical conditions, fertility plans, and the duration of symptoms.
Total testosterone should generally be measured in the morning, preferably while fasting, using an accurate and reliable assay. A low result should be confirmed with a second morning measurement on a separate day.
Depending on the findings, clinicians may assess free testosterone, LH, FSH, prolactin, and sex hormone-binding globulin (SHBG) to help identify the underlying cause.
A clinician may also evaluate blood count, metabolic health, sleep disorders, prostate-related risk, and other factors relevant to the patient’s medical history and proposed treatment.
A total testosterone level below 300 ng/dL is used as a reasonable diagnostic threshold in some clinical guidance. However, it is not a stand-alone diagnosis. Symptoms, repeat testing, assay quality, and the full clinical picture must be considered.
Not every man with a low testosterone result needs immediate hormone treatment. In some cases, potentially reversible contributors should be addressed first.
A broader health assessment may consider:
Lifestyle measures are not a substitute for TRT when a man has a clear medical cause of testosterone deficiency. However, they can be an important part of an individualized treatment plan.
Starting treatment is not the end of the process. Follow-up helps determine whether treatment is appropriate, whether symptoms are improving, and whether adverse effects are developing.
| Monitoring area | Why it matters |
|---|---|
| Testosterone levels | Helps assess whether treatment is achieving an appropriate level |
| Symptoms and quality of life | Shows whether treatment is producing meaningful improvement |
| Hematocrit and complete blood count | Helps identify an excessive rise in red blood cell concentration |
| Blood pressure | Helps identify possible treatment-related changes |
| Prostate-related assessment | Supports individualized prostate risk monitoring |
| Adverse effects | Helps identify problems requiring treatment adjustment |
The timing of testosterone testing can vary according to the formulation being used. For example, the timing of a blood test in relation to an injection or gel application can affect the result.
Patients should follow the monitoring schedule provided by their prescribing clinician. They should not increase, decrease, or discontinue testosterone on their own.
Treatment should also be reassessed if testosterone levels normalize but the symptoms that prompted therapy do not meaningfully improve after an appropriate treatment period.
Not necessarily in every situation, but treatment may be long-term when an underlying condition causes persistent testosterone deficiency.
The need for continued treatment should be reassessed through regular clinical review. This includes evaluating whether symptoms have improved, whether testosterone levels are appropriate, and whether adverse effects have developed.
Stopping TRT can cause testosterone levels to fall. The body’s natural hormone production and sperm production may take time to recover, and recovery varies between individuals.
Men should discuss discontinuation with their prescribing clinician rather than changing their treatment independently.
Regulatory guidance on testosterone therapy has evolved as additional clinical evidence has become available.
In 2025, the FDA removed the class-wide boxed warning about increased major adverse cardiovascular events after reviewing the cardiovascular safety findings from the TRAVERSE trial. However, it also required labeling changes communicating the risk of increased blood pressure following ambulatory blood pressure monitoring studies.
In June 2026, the FDA requested further updates to testosterone product labeling following a review of additional data and existing evidence. These changes included removing the previous limitation concerning age-related hypogonadism and revising safety information related to prostate cancer and benign prostatic hyperplasia.
These regulatory changes do not mean that every man experiencing age-related symptoms should start TRT. A confirmed diagnosis, individualized assessment, and ongoing monitoring remain essential.
At Holistic Medical Wellness, hormone-related concerns should be considered within the context of a person’s broader health—not just a single laboratory result.
An evaluation of low testosterone may involve reviewing symptoms, hormone measurements, sleep, metabolic health, body composition, medication history, and other factors that could contribute to hormonal changes.
For men considering testosterone replacement therapy, the goal should be to understand whether treatment is medically appropriate, establish realistic expectations, and create a monitoring plan that accounts for individual risks and health goals.
TRT may benefit men with appropriately diagnosed testosterone deficiency, but it is not a shortcut to better energy, muscle growth, or longevity.
A physician-guided approach can help patients understand their options and make informed decisions about their hormone health.
In men with confirmed testosterone deficiency, TRT may improve sexual desire, certain aspects of sexual function, lean body mass, bone mineral density, and some cases of anemia. The benefits vary, and treatment does not guarantee improvements in energy, mood, or physical performance.
Important risks include reduced sperm production and fertility, increased hematocrit, possible blood pressure changes, fluid retention, acne, and potential cardiovascular or thromboembolic concerns. Individual risks depend on medical history, treatment formulation, dose, and monitoring.
A major cardiovascular safety trial found no increased rate of its primary outcome of cardiovascular death, nonfatal heart attack, or nonfatal stroke among the men studied. However, higher incidences of atrial fibrillation, acute kidney injury, and pulmonary embolism were observed in the testosterone group. The findings do not establish that TRT is risk-free for all patients.
Yes. External testosterone can suppress the hormones responsible for stimulating sperm production. This may reduce sperm counts and cause infertility during treatment. Men who want to have children should discuss fertility-preserving approaches with a specialist before starting TRT.
In some men, addressing excess body weight, poor sleep, inadequate nutrition, inactivity, and underlying medical conditions may improve testosterone levels or related symptoms. The effect varies, and lifestyle changes cannot replace treatment when a clear medical cause of testosterone deficiency is present.
Diagnosis generally requires compatible symptoms and at least two separate morning testosterone measurements showing consistently low levels. Additional hormone tests and medical evaluation may be needed to identify the cause.
Treatment may be long-term when an underlying condition causes persistent testosterone deficiency. The need for continued treatment should be reassessed through regular clinical review. Stopping TRT can cause testosterone levels to fall, and natural hormone production may take time to recover.
Men planning fertility in the near future, men with certain prostate or breast cancer concerns, elevated hematocrit, untreated severe sleep apnea, uncontrolled heart failure, recent heart attack or stroke, or thrombophilia may be advised against starting TRT under clinical guidelines. A clinician should assess each individual's circumstances.
Not without an appropriate medical assessment. Fatigue and reduced muscle strength have many possible causes. TRT is intended to treat clinically established testosterone deficiency, not to serve as a general performance-enhancing or anti-aging treatment.
Routine population-wide screening of asymptomatic men is not generally recommended by the Endocrine Society. Testing is more appropriate when symptoms, clinical findings, or specific medical circumstances suggest testosterone deficiency.
This article is intended for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. Testosterone replacement therapy should only be considered after an appropriate clinical evaluation and discussion of potential benefits, risks, fertility implications, and monitoring requirements. Do not start, change, or stop hormone therapy without consulting a qualified healthcare professional.